Insider · SEC Form 4 filer

John Orwin

Companies

Where they file as an insider

Anaptysbio (ANAB) Director Latest filing Sep 15, 2026
First Tracks Biotherapeutics (TRAX) Director Latest filing Sep 15, 2026
Travere Therapeutics (TVTX) Director Latest filing May 19, 2026
Atreca (BCEL) President & CEO, Director Latest filing Apr 11, 2024
Seagen (SGEN) Director Latest filing Dec 14, 2023

Track record

Did their buys beat the typical stock?

Open-market buys1
Quarters checked 6 months later0
Beat the typical stock —
Quarters too new to check0

Too soon to tell. None of their buys has a finished 6-month check yet.

Atreca (BCEL) Bought Apr 11, 2024 · $0 · 1 shares Not counted Not counted. We have no fund price for this stock on both Jun 30, 2024 and Dec 31, 2024.

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist